Advanced Research in GPCR Signal Transduction and Cancer Biology
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 2751
Special Issue Editors
Interests: signal transduction; molecular pharmacology; G protein coupled receptors (GPCR); G protein; pancreatic cancer; placenta/chorion mesenchymal stem cells
Interests: stem cells; epigenetic mechanisms; noncoding RNAs; cancer stem cells
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Each cell shapes its architecture, drives metabolism, and modulates the transcriptome based on extracellular stimuli received from the rest of the body. The largest class of “protein sensors” are G protein coupled receptors (GPCRs) that collect thousands of stimuli with high specificity and provide cells with spatial information integrated over time. Thanks to this evolutionary conserved molecular machinery, cells undertake complex functions such as chemotaxis, vision, cardiac rhythm, and bone remodeling.
CXCR4 and a relatively small number of GPCRs have been extensively investigated in oncogenesis but are largely overlooked. Modern “-omics” approaches offer a wealth of data; however, signaling molecules such as GPCRs and G-proteins are often expressed at low levels, and their oncogenic function is in most cases independent of mutations. For these reasons, mining GPCR signaling via bioinformatic analyses remains poorly exploited. The potential impact that could derive for the clinic is great since about half of the targets for prescribed drugs relate to GPCRs.
This Special Issue aims to describe progress in mapping GPCR signaling and deciphering the informatic infrastructure of cancer cells from the perspective of intercepting pro-oncogenic signals. A better understanding of dynamic interactions and molecular compartmentalization of GPCRs, interacting molecules, downstream second messengers, kinases, transcription factors, etc. is expected to lead to more specific treatments and finally surpass antimitotic drugs and achieve personalized therapies.
Dr. Giulio Innamorati
Dr. Giorgio Malpeli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
